AstraZeneca: takes stake in Cellectis

(CercleFinance.com) - AstraZeneca announced today that it has made an equity investment in Cellectis, a clinical-stage biotechnology company.


For information, in Q4 2023, Cellectis received an upfront payment of $105m from AstraZeneca, which included an initial cash payment of $25m.

An additional equity investment of $140m, at $5/share, has closed.

After this second investment, AstraZeneca holds a total stake of around 44% in Cellectis.


Copyright (c) 2024 CercleFinance.com. All rights reserved.